Clinical Trial Update: Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL" [Phase 2]

View source ↗

Summary

This is an ongoing Phase 2 clinical trial comparing obinutuzumab with rituximab in CD20-positive acute lymphoblastic leukemia, currently recruiting. The trial i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Obinutuzumab (obinutuzumab)
• Rituximab (rituximab)

Snippet

Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology | Conditions: CD20-positive Acute Lymphoblastic Leukemia | Phase 2 | Status: RECRUITING